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food; average intake 103 ± 4 mg/kg/day). Half of the rats in each group was studied after
12 weeks of treatment, at the age of 34 weeks; the other half at the age of 54 weeks.At
the end of treatment, indexes of systemic and regional hemodynamics were measured in
conscious instrumented rats. Radiomicrospheres were used for flow measurements.
Results: E decreased mean arterial pressure after 12 and 32 weeks of treatment; it did
not affect left ventricular (LV) mass; and E decreased LV hydroxyproline concentration
(an estimate of collagen) after 32 weeks of therapy. E did not affect coronary blood flow
and resistance under basal conditions, but decreased minimal coronary vascular resis-
tance (MCVR) and increased coronary flow reserve, measured after dipyridamole infu-
sion.
Conclusions: Extended therapy with E improved coronary hemodynamics and reduced 
myocardial collagen suggesting that aldosterone may be involved in mediating age- and 
hypertension-related cardiac fibrosis.
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Clinic, Berlin, Germany
Background: Aliskiren is a potent and selective renin inhibitor currently in clinical devel-
opment. The purpose of this study was to compare the antihypertensive responses of i.v.
and p.o. aliskiren to those of enalapril(at) and valsartan in double transgenic rats (dTGR)
expressing the human angiotensinogen and renin genes.
Methods: Studies were conducted on 5.5- to 10.7-week-old male dTGR [(h-REN)L10J x
(h-AOGEN)L1623] instrumented with chronically indwelling femoral arterial and venous
catheters (exteriorized through a tether system). Aliskiren (hemifumarate salt) was
administered i.v. (0.003-3 mgEq/kg) or p.o. (0.3-30 mgEq/kg) as single or escalating
cumulative doses on a given day followed by at least 3 days of recovery before the next
experiment. Enalapril(at) (0.003-1 mgEq/kg i.v.; 0.01-1 mgEq/kg p.o.) and valsartan
(0.003-1 mg/kg i.v.; 0.1-10 mg/kg p.o.) were given in a like manner. Mean arterial pres-
sure (MAP) was monitored before (“baseline”) and for up to 72 hours after dosing. In sep-
arate experiments, arterial blood samples were collected for pharmacokinetic analyses of
aliskiren.
Results: Each agent dose-dependently (i.v. and p.o.) lowered MAP (baselines ~203
mmHg; range, 146-272 mmHg; maximal decreases ~60-70 mmHg) . Aliskiren, enalapri-
lat, and valsartan were equipotent as i.v. antihypertensives, whereas p.o. aliskiren tended
to be less potent than p.o. enalapril and valsartan due to its lower functional and pharma-
cokinetic oral bioavailabilities. Aliskiren (p.o.) rapidly lowered MAP (15-30 minutes post-
dosing) reflecting the short time (15 minutes) to peak plasma concentration (14.8 nM
@30 mgEq/kg). In spite of its relatively rapid plasma clearance (elimination half-life: 2.8
hours; clearance: ~10 L/hour/kg), aliskiren exhibited a prolonged duration of action (MAP
recovery required up to 72 hours).
Conclusion: Aliskiren is a rapidly absorbed, potent, and long-acting antihypertensive in
dTGR. Our results extend previous observations in other preclinical models and support
the continued development of aliskiren as the first agent in a novel class of renin inhibi-
tors with the potential for treatment of hypertension.
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Background: An administration time-dependent effect of low-dose aspirin (ASA) on blood
pressure (BP) has been previously documented in normotensive volunteers, patients
with mild hypertension, and pregnant women at high risk for preeclampsia [Hermida et al.
Hypertension. 2003;41:651-656 and 2003;41:1259-1267]. We have extended these
results by investigating the influence of ASA on BP in previously untreated hypertensive
patients who received ASA at different times of the day according to their rest-activity
cycle.
Methods: We studied 264 untreated patients with mild hypertension (101 men),
43.6±12.6 (mean±SD) years of age, randomly divided in 3 groups: non-pharmacological
hygienic-dietary recommendations (HDR); the same HDR and ASA (100 mg/day) on
awakening; or HDR and ASA (100 mg/day) before bedtime. BP was measured every 20
min from 07:00 to 23:00 hours and every 30 min at night for 48 consecutive hours before
and after 3 months of intervention. The circadian pattern of BP in each group was estab-
lished by population multiple-component analysis.
Results: After 3 months of non-pharmacological intervention, there was a small and non-
significant reduction of BP (0.4 and 0.5 mm Hg for systolic and diastolic BP; P>0.584).
BP was slightly elevated after ASA on awakening, mainly during nocturnal resting hours
(increase of 2.7 and 1.5 mm Hg in the 24-hour mean of systolic and diastolic BP;
P<0.020). A highly significant BP reduction was, however, observed in the patients who
received ASA before bedtime (decrease of 7.1 and 4.6 mm Hg in systolic and diastolic
BP, respectively; P<0.001).
Conclusion: This trial corroborates the highly significant administration-time dependent
effect of low-dose ASA on BP in untreated patients with mild hypertension. Results indi-
cate that the timed administration of low-dose ASA with respect to the rest-activity cycle
of each patient could provide a valuable approach not just for the secondary prevention
of cardiovascular disease, but also in the added BP control of patients with mild essential
hypertension and poor compliance with HDR.
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INTRODUCTION: More than 60% of patients with ischemia also have hypertension
(HTN) and are at high risk for CV events. This analysis evaluates BP control, angina fre-
quency and episodes and CV events in CAD patients with HTN and ischemia (classic
angina pectoris or concordant abnormalities on 2 different types of stress tests [e.g. ST
segment or wall motion and perfusion]) and without prior MI. METHODS: In the prospec-
tive INternational VErapamil SR/trandolapril STudy (INVEST), patients with HTN and
CAD were randomized to either a verapamil-SR based (Ve) or atenolol based (At) treat-
ment strategy and followed 2.7 years (mean). Trandolapril and HCTZ were available in
both strategies to achieve JNC VI BP goals (<140/<90 or <130/<85 in diabetes or renal
dysfunction). The primary outcome (PO) was time to first occurrence of death (all-cause),
nonfatal MI or nonfatal stroke. This analysis includes 10,617 patients with ischemia at
baseline. RESULTS: See table. BP reduction, control and outcomes were similar com-
paring strategies. At 24 months, presence of angina was also similar and reduced from
baseline. Heart rate (HR) and systolic BP-HR product were significantly lower in the At
strategy, however episodes of angina / month was significantly lower in the Ve strategy.
CONCLUSIONS: Despite decreased indices of cardiac oxygen demand in the At strat-
egy, patients in the Ve strategy had a greater reduction of anginal episodes, suggesting
an alternate mechanism of action for reduced anginal symptoms from verapamil-SR . 
Cardiovascular Effects of Eplerenone
Control
(34w)
E
(34w)
Control
(54w)
E
(54w)
Mean Arterial
Pressure (mmHg)
178±4 157±3* 179±6 165±3*
LV Mass
(mg/g)
2.89±0.04 2.83±0.05 3.16±0.07 3.05±0.05
LV Hydroxyproline
(mg/g)
4.62±0.21 4.47±0.24 6.23±0.24 5.41±0.18
Coronary Blood
Flow (ml/min/g)
5.86±0.33 5.40±0.20 4.89±0.32 4.25±0.20
Coronary Vascular
Resistance (U/g)
30.94±1.31 29.53±1.38 38.68±3.82 39.51+1.74
MCVR (U/g) 14.65+1.01 11.74+0.51* 20.18+1.45 15.69±0.92*
Coronary Flow
Reserve (ml/min/g)
4.50±0.40 5.94±0.36* 3.12±0.47 5.32±0.57*
AT ENTRY Verapamil-
SR Strategy(n=5,335)
Atenolol 
Strategy(n=5,282)
p value
Mean Age (yr) (SD) 65 (10) 65 (10) 1.00
Mean BMI (kg/m2) 
(SD)
29 (6) 30 (6) 0.12
% w/ Angina 95 95 0.84
Mean # Angina 
Episodes / Mo (SD)
5.2 (8.4) 5.2 (7.2) 0.66
OUTCOME DATA Unadjusted HR 
(95% CI)
Primary Outcome n 
(%)
361 (7) 332 (6) 1.08 (0.93-1.26)
Death n (%) 285 (5) 279 (5) 1.02 (0.86-1.20)
Fatal and nonfatal MI n 
(%)
135 (3) 129 (2) 1.04 (0.82-1.33)
Fatal and nonfatal 
Stroke n (%)
62 (1) 60 (1) 1.03 (0.72-1.47)
AT 24 MONTHS Verapamil-
SR Strategy(n=3,788)
Atenolol 
Strategy(n=3,803)
p value
Mean Systolic BP 
(mmHg) (SD)
132 (15) 132 (16) 0.99
Mean Diastolic BP 
(mmHg) (SD)
78 (9) 78 (8) 0.95
BP Control (JNC VI) % 64 63 0.51
Mean HR (bpm) (SD) 73 (8) 70 (9) <0.001
Mean SBP-HR 
Product (SD)
9647 (1638) 9269 (1654) <0.001
% w/ Angina 42 42 0.88
Mean # Angina 
Episodes / Mo (SD)
2.4 (4.36) 2.8 (4.92) 0.05
